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This paper is covering new, simplistic method of obtaining the system for controlled delivery of the ascorbic acid. Copolymer poly
(D,L-lactide-co-glycolide)(DLPLG)nanoparticlesareproducedusingphysicalmethodwithsolvent/nonsolventsystemswhereob-
tained solutions were centrifuged. The encapsulation of the ascorbic acid in the polymer matrix is performed by homogenization
of water and organic phases. Particles of the DLPLG with the diﬀerent content of ascorbic acid have diﬀerent morphological char-
acteristics, that is, variable degree of uniformity, agglomeration, sizes, and spherical shaping. Mean sizes of nanoparticles, which
contain DLPLG/ascorbic acid in the ratio 85/150%, were between 130 to 200nm depending on which stereological parameters are
considered (maximal diameters Dmax, feret X, or feret Y). By introducing up to 15% of ascorbic acid, the spherical shape, size,
and uniformity of DLPLG particles are preserved. The samples were characterized by infrared spectroscopy, scanning electron
microscopy, stereological analysis, and ultraviolet spectroscopy.
Copyright © 2007 Magdalena M. Stevanovi´ c et al. This is an open access article distributed under the Creative Commons
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.
1. INTRODUCTION
The systems for controlled delivery of the medicaments in
the body are causing real revolution in the medicine and
pharmacy in the recent years, and all in favor of better med-
ical treatments of the patients [1]. Using the system for the
controlled and balanced release of medicaments, opposing
to standard and conventional methods, constant and uni-
form concentration of medicament in the body is achieved
throughout longer period of time. Copolymer poly(D,L-
lactide-co-glycolide) is used for the controlled delivery of
several classes of medicaments like anticancer agents, anti-
hypertensive agents, immunomodulatory drugs, hormones,
and macromolecules like nucleic acid, proteins, peptides,
antibodies, DLPLG nanospheres are very eﬃcient mean of
transdermal transport of medicaments in the body, for ex-
ample, ascorbic acid [2]. DLPLG polymer particles allow the
encapsulationofthemedicamentwithinthepolymermatrix,
where the principle requirement for the controlled and bal-
anced release of the medicament in the body is the particle’s
ideal spherical shape and narrow distribution of its size. The
size and shape of the particles play key role in their adhe-
sion and interaction with the cell. Dynamic of the release
(paceandconcentration)dependsofthemorphology,thatis,
structure of the copolymer. The chemical structures, molec-
ular weight, composition, as well as the synthesis conditions,
are parameters which inﬂuence the ﬁnal morphology of the
polymer. The direct relation between these parameters and
morphology is inadequately examined thus making it a topic
of many researches. Depending on the nature and matrix of
the selected material, methods of obtaining polymer parti-
cles can be divided in general into dispersion of the polymer
solution method, polymerization of the monomer method,
and coacervation [3–6]. The PLGA spheres obtained with
emulsion process are in range of 150–200µm[ 7], 45µm
[8], 30µm[ 9]. With modiﬁed emulsion method, the parti-
c l es i z e sa r ed e c r e a s e dt o1 0µm[ 10]. Further modiﬁcation
of the process for synthesis of the particles, that is, emulsi-
ﬁcation solvent evaporation method, the obtained particles
are in nanometer scale of 570–970nm [11] and 244–260nm2 Journal of Biomedicine and Biotechnology
[12–14]. The latest researches in this ﬁeld indicated the pos-
sibility of producing DLPLG spheres with average diameter
under 100nm [15]. Controlling the conditions of obtain-
ing DLPLG by solvent/nonsolvent method, changing the pa-
rameters like aging time, after adding nonsolvent, time and
velocity of centrifugal processing, it is possible to inﬂuence
on morphology (size and shape) and uniformity of DLPLG
p o l y m e rp o w d e r[ 16]. DLPLG powder with short aging time
with nonsolvent and longest time and velocity of the cen-
trifugal processing has smallest particles and highest unifor-
mity. DLPLG copolymer has potential to be used for trans-
port of ascorbic acid in the body, thus considerably increas-
ing its eﬃciency. Ascorbic acid reduces free radicals, and in
that way damages created by oxidative stress which is a root
cause of, or at least associated with, many diseases are min-
imized. The aim of this research is obtaining the nanopar-
ticles of copolymer poly(D,L-lactide-co-glycolide) in which
ascorbic acid is encapsulated, as well as examining the inﬂu-
ence of the synthesis method on morphological characteris-
tics of poly(D,L-lactide-co-glycolide) particles with the dif-
ferent content of ascorbic acid.
2. MATERIALS AND METHODS
2.1. Materials
Poly(D,L-lactide-co-glycolide) (DLPLG) was obtained from
Durect, Lactel, Adsorbable Polymers International and had a
lactide to glycolide ratio of 50 : 50. Molecular weight of poly-
merwas40000–50000g/mol.Timeofcompleteresorptionof
this polymer is 4–8 weeks. Molecular weight of ascorbic acid
was 176.13g/mol. Polyvinyl alcohol (PVA) was used with a
98% hydrolization degree. All other chemicals and solvents
were of reagent grade.
2.2. Preparationofnanoparticles
Copolymer powder DLPLG was obtained by means of
physical methods from commercial granules using sol-
vent/nonsolvent systems (Figure 1). Commercial granules
poly(D,L-lactide-co-glycolide) (0.05g) were dissolved in
1.5mL of acetone and, after approximately two hours, 2mL
of methanol was added into solvent mixture. DLPLG pre-
cipitated by the addition of methanol and the solution be-
camewhitish.Thepolymericsolutionthusobtainedwasvery
slowly poured into 20mL of aqueous PVA solution (0.02%
w/w) while continuous stirring at 1200rpm by a stirrer. Af-
terthat,thesolutionwascentrifugedanddecanted.Timeand
velocity of the centrifugal processing were 120 minutes and
4000rpm. PVA is used as a stabilizer which creates negative
charge of the DLPLG particles, that is, it creates negative zeta
potential [17]. By creating speciﬁc zeta potential, PVA brings
to reduction of agglomeration of the particles. All used so-
lutions are nontoxic for environment. The ascorbic acid was
encapsulated into the polymer matrix by means of homog-
enization of water and organic phases. The water solution
with the variable ratio of the ascorbic acid was added to the
polymer solution. This was followed by the precipitation us-
ing alcohol methanol. In the particles of DLPLG copolymer,
DLPLG + acetone Centrifugation
Dissolving in two
hours
+W a t e rs o l u t i o n
of ascorbic acid Stabilization with
zeta potential
Decanting + Methanol
Precipitation
Drying
Aqueous PVA
solution
DLPLG/ascorbic acid
nanoparticles
Figure 1: Schematics for obtaining of the DLPLG/ascorbic acid
nanoparticles.
diﬀerent concentration of ascorbic acid has been encapsu-
lated with ratios 85% DLPLG to 15% ascorbic acid, 70%
DLPLG to 30% ascorbic acid, 50% DLPLG to 50% ascorbic
acid, and 30% DLPLG to 70% ascorbic acid.
2.3. Infrared(IR)spectroscopymeasurements
The quality analysis of the samples was performed with
IR spectroscopy. The IR measurements were performed on
Perkin-Elmer 983G infrared spectrophotometer, using the
KBr pellet technique, in the frequency interval of 400–
4000cm−1.
2.4. Scanningelectronmicroscope(SEM)observation
The morphology of obtained particles of DLPLG was ex-
amined by scanning electron microscope (SEM) JEOL JSM-
646OLV. The powder samples for SEM analysis were coated
withgoldusingthephysicalvapordeposition(PVD)process.
Samples were covered with gold (SCD 005 sputter coater),
using 30mA current from the distance of 50mm during 180
seconds.
2.5. Stereologicalanalysis
The particle size and morphology were examined using the
area analysis method [18, 19] by semiautomatic image ana-
lyzer (Videoplan, Kontron), connected with a scanning elec-
tron microscope (SEM). From 200 to 300 particles in the
SEM were measured and the following parameters were de-
termined: area section Aa, perimeter Lp, maximal diameter
of the particle Dmax, feret x and feret y, and form factor (fL)
(Figure 2).
2.6. Ultraviolet(UV)spectroscopy
Release of the ascorbic acid from DLPLG particles in vitro in
physiological solution (0.9% sodium chloride in water) was
studied with UV spectroscopy. The UV measurements wereMagdalena M. Stevanovi´ ce ta l . 3
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Figure 2: Shematics of the stereological parameters: (a) area (Aa); (b) perimeter (Lp); (c) feret x and feret y (d) maximal particle diameter
(Dmax); (e) form factor (fL).
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Figure 3: IR spectra of the DLPLG nanoparticles.
performedonPerkin-ElmerLambda35UV-Visspectropho-
tometer in the frequency interval of 200–400nm.
3. RESULTS AND DISCUSSION
The IR spectra in Figure 3 illustrate all characteristic groups
for copolymer poly(D,L-lactide-co-glycolide). The IR spec-
tra of DLPLG show peaks at 2994, 2946, 2840 (CH bend),
1769 (C=O ester), 1460, 1424, 1371 (CH3), 1150, 1069984
(C−O stretch), 732509 (CH-bend) cm−1 while the band
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Figure 4: IR spectra of the DLPLG/ascorbic acid 85/15% nanopar-
ticles.
on 3100–3600cm−1 belongs to the OH group of the water
molecule [20].
Comparing the obtained IR spectra for DLPLG and
ascorbic acid (Figure 4) with the IR spectra charecteris-
tics for ascorbic acid shown in the literature [21, 22],
it is conﬁrmed that obtained nanoparticles are composed
of poly(D,L-lactide-co-glycolide) and ascorbic acid. Besides
the characteristic groups for copolymer DLPLG, the four
O−H bands of ascorbic acid could be assigned by means
of infrared investigations at 3528, 3411, 3317, 3217cm−1.
The spectra show bands that can be assigned to CH3,4 Journal of Biomedicine and Biotechnology
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Figure 5: SEM images of (a) DLPLG nanoparticles; (b) DLPLG/ascorbic acid 85/15% nanospheres; (c) DLPLG/ascorbic acid 70/30%; (d)
DLPLG/ascorbic acid 50/50%; (e) DLPLG/ascorbic acid 30/70%.
CH2, or CH groups in the ascorbic acid environment at
2720cm−1 and the spectra also clearly show the band
corresponding to C=O groups at 2916cm−1. The bands
that correspond to the wave number 1754cm−1 belong to
C=C groups, 1673cm−1 C−O−C, and 1020cm−1 C−O,
respectively.
The morphological characteristics of the obtained
DLPLG particles, with and without encapsulated ascor-
bic acid, were examined with a scanning electron micro-
scope. From the SEM recordings of DLPLG particles with-
out ascorbic acid (Figure 5(a)), it is visible that the particles
have spherical shape, smooth surface, low level of agglom-
eration, and high level of uniformity—higher than other
samples. From the SEM recordings of the second sample
(Figure 5(b)), where DLPLG copolymer has encapsulated
ascorbic acid in ratio DLPLG/ascorbic acid 85/15%, it is vis-
ible that particles also have spherical shapes, that is, spheri-
cal shape of the initial DLPLG has not been compromised.
DLPLG/ascorbic acid 85/15% nanoparticles are uniform
with sizes from 130 to 200nm depending on which stere-
ological parameters are considered (Dmax, maximum di-
ameters, feret X, or feret Y). The particles of the sample
DLPLG/ascorbic acid 70/30% (Figure 5(c)) also have spheri-
cal shapes, but their sizes are increased. In case of the fourth
sample, DLPLG/ascorbic acid 50/50% (Figure 5(d)) unifor-
mity is perturbated, particles have both spherical and irreg-
ular shapes and they are much agglomerated. For the ﬁfth
sample, DLPLG/ascorbic acid 30/70% (Figure 5(e)), the par-
ticles were very much agglomerated, so stereological analyses
could not be performed.Magdalena M. Stevanovi´ ce ta l . 5
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Figure 6: Comparative results of the stereological examining of
DLPLG particles and particles with diﬀerent ratio of DLPLG and
ascorbic acid, DLPLG/ascorbic acid 85/15%, DLPLG/ascorbic acid
70/30%, DLPLG/ascorbic acid 50/50%, based on maximal diameter
o ft h ep a r t i c l eD m a x .
The stereological analysis is giving us the parameters
which are characterizing the particle sizes (area section—
Aa, perimeter—Lp, maximal diameter—Dmax, and feret’s
diameters) and parameter which is characterizing the par-
ticle shape (perimeter form factor—fL). For all parameters,
minimum, maximum, and mean values were recorded and
presented in Table 1.
Based on the obtained results of the stereological analysis
of DLPLG particles, it is visible that they are uniform, their
average mean size varies from 0.15 to 0.23µm depending on
the stereological parameter taken in consideration (Dmax,
feret X, or feret Y) (Table 1). Dmax values range from 0.09
to 0.39 µm with particle’s mean size 0.23µm( Figure 6). Fig-
ures 7 and 8 present comparative results of DLPLG particles
with and without ascorbic acid based on their area section
and perimeter form factor.
From the comparative results of the stereological analy-
sis of the area section (Aa) of DLPLG with and without en-
capsulated ascorbic acid (Figure 7)a sw e l la sc o m p a r a t i v er e -
sults of the perimeter form factor (fL), (Figure 8) we can see
that DLPLG particles without ascorbic acid have the small-
est area section (minimum value for Aa is 0.02µm2and max-
imum is 0.08µm2) and the highest mean value of perime-
ter form factor which is 0.89. Nanoparticles DLPLG/ascorbic
acid 85/15% have minimum Dmax of 0.09µm and maxi-
m u mD m a xo f0 . 4 9 µm, where their mean size is 0.20µm
(Figure 6). The mean value of the area section is 0.03µm2
(Figure 7)andoftheperimeterformfactoris0.87(Figure 8).
For particles DLPLG/ascorbic acid 70/30%, minimum Dmax
is0.30µmandmaximumDmaxis2.59µm,wheretheirmean
9 8 7 6 5 4 3 2 1 0
Aa (µm2)
0
20
40
60
80
100
C
u
m
.
f
r
e
q
.
(
%
)
DLPLG
DLPLG/ascorbic acid 85/15%
DLPLG/ascorbic acid 70/30%
DLPLG/ascorbic acid 50/50%
Figure 7: Comparative results of the stereological examining of
DLPLG particles and particles with diﬀerent ratio of DLPLG and
ascorbic acid, DLPLG/ascorbic acid 85/15%, DLPLG/ascorbic acid
70/30%, DLPLG/ascorbic acid 50/50%, based on area section Aa.
size is 0.67µm( Figure 6), which indicates that the unifor-
mity is decreased and size is increased. The mean value of
the area section is 0.41µm2 (Figure 7) and of the perimeter
form factor is 0.77 (Figure 8). For particles DLPLG/ascorbic
acid 50/50%, minimum Dmax is 0.28µm and maximum
Dmaxis4.51µm,wheretheirmeansizeis1.60µm(Figure 6).
The mean size of the area section is 2.30µm2 (Figure 7)
and of the perimeter form factor is 0.74 (Figure 8). In case
of DLPLG/ascorbic acid 30/70%, the stereological analysis
could not be performed.
Thereleaseamountoftheascorbicacidfromthepolymer
particles was determined periodically during the eight weeks
with UV spectroscopy. A calibration curve of the ascorbic
acid in physiological solution at diﬀerent concentrations has
been prepared using the speciﬁc absorbance peak of the
ascorbic acid at 264nm.
Figure 9 shows the dependence of the maximum ab-
sorption from the degradation time in cases of DLPLG
without ascorbic acid, DLPLG/ascorbic acid 85/15%,
DLPLG/ascorbic acid 70/30%, and DLPLG/ascorbic acid
50/50%. This absorbance is correlated with the calibra-
tion curve and amount of ascorbic acid is determined
in percentages. Figure 10 gives cumulative curves of the
release of the ascorbic acid in percentages over the pe-
riod of time of the degradation. Figure 10 also shows the
relative review in percentages of the ascorbic acid release
in periods of up to two days, 2–11, 11–17, 17–24, 24–31,
31–39, 39–46, and 46–55 days. In the ﬁrst 24 days of
the degradation, for all samples, less than 10% of the
encapsulated ascorbic acid have been released. For all6 Journal of Biomedicine and Biotechnology
Table 1: Results of the stereological analysis of DLPLG and DLPLG/ascorbic acid particles.
Ratio DLPLG/
ascorbic acid
Lp (µm) Aa (µm)2 Dmax (µm) Feret x (µm) Feret y (µm) fL
Min Max Mean Min Max Mean Min Max Mean Min Max Mean Min Max Mean Min Max Mean
100% DLPLG 0.19 1.12 0.81 0.02 0.08 0.03 0.09 0.39 0.23 0.09 0.25 0.15 0.09 0.28 0.19 0.49 0.91 0.89
85/15% 0.37 1.39 0.70 0.01 0.14 0.03 0.09 0.49 0.20 0.05 0.43 0.15 0.03 0.26 0.13 0.57 1.00 0.87
70/30% 0.95 8.92 2.40 0.06 4.63 0.41 0.30 2.59 0.67 0.17 2.19 0.46 0.17 1.65 0.48 0.48 0.92 0.77
50/50% 1.62 14.23 5.86 0.20 13.25 2.30 0.28 4.51 1.60 0.21 4.13 1.13 0.15 3.10 1.09 0.35 0.97 0.74
30/70% —— ——— —— ——— ——— ——— ——
1 0.8 0.6 0.4 0.2 0
Perimeter form factor, fL
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Figure 8: Comparative results of the stereological examining of
DLPLG particles and particles with diﬀerent ratio of DLPLG and
ascorbic acid, DLPLG/ascorbic acid 85/15%, DLPLG/ascorbic acid
70/30%, DLPLG/ascorbic acid 50/50%, based on perimeter form
factor fL.
DLPLG/ascorbic acid samples, the overall quantities of the
encapsulated ascorbic acid have been released in 8 weeks of
the degradation.
4. CONCLUSIONS
The particles obtained with solvent/nonsolvent physical
method and technique of the centrifugal processing have
potential use in transdermal systems for controlled delivery
of ascorbic acid. It is possible to encapsulate ascorbic acid
into DLPLG particles in various concentrations thus pro-
ducing particles with diﬀerent morphological characteris-
tics. The nanoparticles of DLPLG/ascorbic acid with lesser
ratio of ascorbic acid have higher uniformity, lower level
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Figure 9: Comparative curves for the dependence of the maximum
absorbance from the time of the degradation for the DLPLG with
and without ascorbic acid.
of agglomeration, and smaller sizes. The nanoparticles of
DLPLG/ascorbicacid85/15%havesphericalshapesandtheir
sizes are from 130 to 200nm.
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